Catalan Open Research Area. Tesis Doctorals en Xarxa
  • Home
  • About TDX
  • Filter
    • Director
    • Albanell Mestres, Joan (5)
    • Rovira Guerín, Ana (3)
    • Albanell Mestres, Joan (1)
    • Albanell, Joan (1)
    • Arriola, Edurne (1)
    • ... Show more
    • Date of defense
    • 2020 - 2023 (2)
    • 2012 - 2019 (5)
    • Language
    • English (7)
    • ... Show more
    • Keywords and Knowledge Area
    • EGFR (2)
    • HER2+ breast cancer (2)
    • ADCC (1)
    • anti-HER2 antibodies (1)
    • Anti-HER2 targeted therapy (1)
    • ... Show more
    • Subjects
    • 616 - Pathology. Clinical medicine (4)
    • 578 - Virology (1)
    • 616.2 - Pathology of the respiratory system. Complaints of the respiratory organs (1)
    • 616.3 - Pathology of the digestive system. Complaints of the alimentary canal (1)
    • ... Show more
    • Full text availability
    • Open access (6)
    • Embargoed access (1)
    • ... Show more
  • Contact Us
  • Language
    • Castellano
    • Català
    • English
  • Log In
Catalan Open Research Area. Tesis Doctorals en Xarxa
  • Home
  • About TDX
  • FAQ
  • Contact Us
  • Language
    • Castellano
    • Català
    • English
  • Log In
  1. Home
  2. Universitat Pompeu Fabra
  3. Search
JavaScript is disabled for your browser. Some features of this site may not work without it.
Universitat Pompeu Fabra

Search

Show Advanced FiltersHide Advanced Filters

Filters

Use the filters to refine the search results

Now showing items 1-7 of 7

  • Sorting options
  • Relevance
  • Title Asc
  • Title Desc
  • Date Asc
  • Date Desc
  • Results per page
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100

PARP1 expression in breast cancer and effects of its inhibition in preclinical models 

García Parra, Jetzabel (Date of defense: 2012-06-21)

Breast cancer is the main cause of cancer death in women. Improved treatments, prevention programs and earlier detection are reducing the rate of death; however, there is still a high percentage of ...

MET and epithelial to mesenchymal transition as novel targets in small cell lung cancer 

Cañadas Castillo, Israel (Date of defense: 2013-06-25)

Small cell lung carcinoma (SCLC) is a highly lethal disease due to its chemorefractory nature after first line treatment. The mechanisms to overcome this resistance have remained elusive to tackle up ...

Cancer-associated fibroblasts and response to anti-HER2 monoclonal antibodies in breast cancer 

Guardia Valenzuela, Cristina (Date of defense: 2019-12-19)

El cáncer de mama HER2-positivo es un subtipo muy agresivo. El desarrollo de terapias anti-diana HER2, particularmente el anticuerpo monoclonal (Mab) trastuzumab, supuso una mejora significativa en el ...

NKG2A blockade as a potential strategy to improve NK cell-mediated ADCC in HER2+ breast cancer 

Suárez Olmos, Jesús (Date of defense: 2023-11-30)

Several studies support the contribution of antibody-dependent NK cell cytotoxicity (ADCC) to the clinical efficacy of anti-HER2 therapeutic antibodies in HER2-positive breast cancer. Novel anti-HER2 ...

Acquired resistance to the anti-EFGR monoclonal antibody cetuximab in colorectal cancer 

Dalmases Massegú, Alba (Date of defense: 2012-06-22)

EGFR is a transmembrane tyrosine kinase receptor from the HER family which, upon ligand stimulation, activates different signaling pathways involved in tumorogenesis. EGFR can be targeted by monoclonal ...

Mechanisms of acquired resistance to anti-EGFR therapies in squamous cell carcinoma 

Guix Arnau, Marta (Date of defense: 2017-12-19)

Targeted therapies against the Epidermal Growth Factor Receptor (EGFR) are useful to treat many human cancers such as non-small cell lung cancer, colorectal cancer and head and neck cancer. However, the ...

Interplay between cancer cells, fibroblasts, immune cells, and resistance to PD-1/PD-L1 inhibition in breast cancer 

Soria Jiménez, Luis (Date of defense: 2023-02-17)

Although the dual anti-HER2 blockade with trastuzumab and pertuzumab monoclonal antibodies has improved the outcome of patients with HER2+ breast cancer, a significant number of patients relapse. ...

Filter

Director

Albanell Mestres, Joan (5)

Rovira Guerín, Ana (3)

Albanell Mestres, Joan (1)

Albanell, Joan (1)

Arriola, Edurne (1)

... Show more

Date of defense

2020 - 2023 (2)

2012 - 2019 (5)

Language

English (7)

... Show more

Keywords and Knowledge Area

EGFR (2)

HER2+ breast cancer (2)

ADCC (1)

anti-HER2 antibodies (1)

Anti-HER2 targeted therapy (1)

... Show more

Subjects

616 - Pathology. Clinical medicine (4)

578 - Virology (1)

616.2 - Pathology of the respiratory system. Complaints of the respiratory organs (1)

616.3 - Pathology of the digestive system. Complaints of the alimentary canal (1)

... Show more

Full text availability

Open access (6)

Embargoed access (1)

CSUC

Accessibility Legal Disclaimer Privacy and Cookie Policy Internal use Collaborations

CSUC LogoSegell BCMetadata under:Public Domain Logo